PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Multhoff, G.* ; Seier, S.* ; Stangl, S.* ; Sievert, W.* ; Shevtsov, M.* ; Werner, C.* ; Pockley, A.G.* ; Blankenstein, C.* ; Hildebrandt, M.* ; Offner, R.* ; Ahrens, N.* ; Kokowski, K.* ; Hautmann, M.* ; Roedel, C.* ; Fietkau, R.* ; Lubgan, D.* ; Huber, R.* ; Hautmann, H.* ; Duell, T.* ; Molls, M.* ; Specht, H.* ; Haller, B.* ; Devecka, M.* ; Sauter, A.* ; Combs, S.E.

Targeted natural killer cell-based adoptive immunotherapy for the treatment of patients with NSCLC after radiochemotherapy: A randomized phase II clinical trial.

Clin. Cancer Res. 26, 5368-5379 (2020)
Postprint DOI PMC
Open Access Green
Purpose: Non-small cell lung cancer (NSCLC) is a fatal disease with poor prognosis. Amembrane-bound form of Hsp70 (mHsp70) which is selectively expressed on high-risk tumors serves as a target for mHsp70-targeting natural killer (NK) cells. Patients with advanced mHsp70-positive NSCLC may therefore benefit from a therapeutic intervention involving mHsp70-targeting NK cells. The randomized phase II clinical trial (EudraCT2008-002130-30) explores tolerability and efficacy of ex vivo-activated NK cells in patients with NSCLC after radiochemotherapy (RCT).Patients and Methods: Patients with unresectable, mHsp70-positive NSCLC (stage IIIa/b) received 4 cycles of autologous NK cells activated ex vivo with TKD/IL2 [interventional arm (INT)] after RCT (60-70 Gy, platinum-based chemotherapy) or RCT alone [control arm (CTRL)]. The primary objective was progression-free survival (PFS), and secondary objectives were the assessment of quality of life (QoL, QLQ-LC13), toxicity, and immunobiological responses.Results: The NK-cell therapy after RCT was well tolerated, and no differences in QoL parameters between the two study arms were detected. Estimated 1-year probabilities for PFS were 67% [95% confidence interval (CI), 19%-90%] for the INT arm and 33% (95% CI, 5%-68%) for the CTRL arm (P = 0.36, 1-sided logrank test). Clinical responses in the INT group were associated with an increase in the prevalence of activated NK cells in their peripheral blood.Conclusions: Ex vivo TKD/IL2-activated, autologous NK cells are well tolerated and deliver positive clinical responses in patients with advanced NSCLC after RCT.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
10.107
2.038
8
24
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Keywords Membrane Heat-shock-protein-70 Hsp70; Lung-cancer; Tumor-cells; Nk Cells; Surface; Chemotherapy; Radiotherapy; Carcinoma; Blockade; Therapy
Language english
Publication Year 2020
HGF-reported in Year 2020
ISSN (print) / ISBN 1078-0432
e-ISSN 1557-3265
Journal Clinical Cancer Research
Quellenangaben Volume: 26, Issue: 20, Pages: 5368-5379 Article Number: , Supplement: ,
Publisher American Association for Cancer Research (AACR)
Publishing Place 615 Chestnut St, 17th Floor, Philadelphia, Pa 19106-4404 Usa
Reviewing status Peer reviewed
Institute(s) Institute of Radiation Medicine (IRM)
POF-Topic(s) 30203 - Molecular Targets and Therapies
Research field(s) Radiation Sciences
PSP Element(s) G-501300-001
Grants DFG-STA1520/1-1
DFG-SFB824/3
TUM
multimmune GmbH
German Research Foundation (DFG)
BMWi (AiF-roject GmbH)
BMBF "Kompetenzverbund Strahlenforschung"
BMBF "Innovative Therapies"
DOI 10.1158/1078-0432.CCR-20-1141
WOS ID WOS:000582352800013
PubMed ID 32873573
Erfassungsdatum 2020-11-17
[➜Report correction]